What is the Aligos Therapeutics, Inc. stock price forecast?

Aligos Therapeutics, Inc. is currently trading at $4.99. View real-time AI analysis on Alpha Lenz.

What is Aligos Therapeutics, Inc. insider trading activity?

View the latest insider trading data for Aligos Therapeutics, Inc. on Alpha Lenz.

What is Aligos Therapeutics, Inc.'s P/E ratio?

View Aligos Therapeutics, Inc.'s valuation metrics on Alpha Lenz.

Aligos Therapeutics, Inc.

NASDAQ · ALGS

$4.99-0.12(-2.35%)Pre-market

Ask about Aligos Therapeutics, Inc.'s future dividend policy...

Alpha Chat Insight

“Aligos Therapeutics, Inc.'s ROE is -196.9%. Explore profitability and growth together.”

Ask for details →

Company Overview

Aligos Therapeutics, Inc. is a biotechnology company focused on the development of novel therapeutics for the treatment of liver diseases and viral infections. The primary purpose of Aligos is to leverage its advanced oligonucleotide and small molecule platforms to discover and develop treatments for chronic liver diseases, including nonalcoholic steatohepatitis (NASH) and hepatitis B virus (HBV) infections. Aligos's pipeline includes various drug candidates in different stages of development, emphasizing innovative solutions aimed at addressing unmet medical needs in these areas. This company's work is critical within the biotechnology and healthcare sectors, significantly contributing to advancements in therapeutic approaches for challenging liver conditions. Aligos Therapeutics holds a key position within the biopharmaceutical market by pushing the boundaries of what's possible in disease treatment through its cutting-edge research and development initiatives.

CEODr. Lawrence M. Blatt MBA, Ph.D.

Websitehttps://www.aligos.com

SectorHealthcare

IndustryBiotechnology

Employees68

Company Statistics

FY 2025

Profile

N/AMarket Cap

$2.19MRevenue

0.00Shares Out

68Employees

Margins

N/AGross

-6649.77%EBITDA

-4024.93%Operating

-1092.36%Pre-Tax

-1106.72%Net

Valuation

N/AP/E

N/AP/B

N/AEV/Sales

N/AEV/EBITDA

N/AP/FCF

Growth (CAGR)

-46.03%Rev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-30.50%ROA

-196.92%ROE

-110.93%ROIC

Financial Health

$18.30MCash & Cash Equivalents

$16.68MNet Debt

65.34%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Aligos Therapeutics, Inc.'s ROE is -196.9%. Explore profitability and growth together.”

Ask for details →

Frequently Asked Questions

Aligos Therapeutics, Inc. (ticker: ALGS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 68 employees.

The current price is $4.99 with a P/E ratio of -x and P/B of -x.

ROE is -196.92% and operating margin is -4024.93%. Annual revenue is $2M.